君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

交易中 02-04 10:01:40

20.360

-0.380

-1.83%

最高20.840	最低20.240	成交量78.72万
今开20.840	昨收20.740	日振幅2.89%
总市值209.10亿	流通市值52.94亿	总股本10.27亿
成交额1,605万	换手率0.30%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":20.36,"timestamp":1770170489129,"preClose":20.74,"halted":0,"volume":787200,"delay":0,"changeRate":-0.018322082931533222,"floatShares":260000000,"shares":1027000000,"eps":-1.3,"marketStatus":"交易中","change":-0.38,"latestTime":"02-04 10:01:40","open":20.84,"high":20.84,"low":20.24,"amount":16045156,"amplitude":0.02893,"askPrice":20.44,"askSize":4800,"bidPrice":20.36,"bidSize":6400,"shortable":3,"etf":0,"ttmEps":-1.048055,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770177600000},"marketStatusCode":2,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":20.74,"openAndCloseTimeList":[[1770168600000,1770177600000],[1770181200000,1770192000000]],"volumeRatio":1.587918,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":34.76,"timestamp":1770170499000,"preClose":35.25,"halted":0,"volume":2667400,"delay":0,"premium":"-48.05"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2608848840","title":"破发股君实生物连亏10年 2020年上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848840","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608848840?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:44","pubTimestamp":1770086649,"startTime":"0","endTime":"0","summary":"中国经济网北京2月3日讯 君实生物 近日发布的2025年年度业绩预告显示，经财务部门初步测算，预计2025年年度实现营业收入250,000.00万元左右，与上年同期相比增长55,168.27万元左右，同比增长28.32%左右。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260203/31993921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK0239","01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2608899609","title":"每日卖空追踪 | 君实生物 02月02日卖空量成交24.44万股，卖空比例为6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899609","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608899609?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021025,"startTime":"0","endTime":"0","summary":"君实生物北京时间02月02日，跌4.12%，卖空量成交24.44万股，较上一交易日减少63.31%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163505a6c9841d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163505a6c9841d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1515","01877"],"gpt_icon":0},{"id":"2608996128","title":"君实生物02月02日遭主力抛售241.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608996128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608996128?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:15","pubTimestamp":1770020150,"startTime":"0","endTime":"0","summary":"02月02日, 君实生物股价跌4.12%，报收20.50元，成交金额8404.3万元，换手率1.55%，振幅6.36%，量比0.44。君实生物今日主力资金净流出241.8万元，连续4日净流出，上一交易日主力净流出295.8万元。近一年数据显示，该股主力连续4日净流出后，次日下跌概率为60.00%，平均跌幅为4.39%。该股近5个交易日下跌13.80%，主力资金累计净流出2185.3万元；近20日主力资金累计净流出1482.6万元，其中净流出天数为13日。该股主力净额占比0.05%，港股市场排名2490/2710。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162125a4727d86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162125a4727d86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01877","BK1161","BK1583"],"gpt_icon":0},{"id":"2608899605","title":"君实生物：预计2025年年度实现营业收入约为25亿元，得益于核心产品拓益®在国内销售收入显著增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899605","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608899605?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:04","pubTimestamp":1770019462,"startTime":"0","endTime":"0","summary":"近日，君实生物发布公告称，预计2025年年度实现营业收入约为25亿元，与上年同期相比增长约28.32%。归母净利润预计约亏损8.73亿元，较上年亏损减少。公告指出，营业收入的增长主要得益于核心产品特瑞普利单抗注射液（拓益）在国内市场的销售收入显著增长。拓益已获批上市的12项适应症全部纳入国家医保目录，并在全球多个国家和地区获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161040a47271da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161040a47271da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877"],"gpt_icon":0},{"id":"2608678899","title":"君实生物盘中异动 大幅下跌5.05%报20.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608678899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608678899?lang=zh_cn&edition=full","pubTime":"2026-02-02 14:58","pubTimestamp":1770015481,"startTime":"0","endTime":"0","summary":"2026年02月02日下午盘14时58分，君实生物股票出现异动，股价快速下跌5.05%。截至发稿，该股报20.300港元/股，成交量344.82万股，换手率1.32%，振幅6.36%。资金方面，该股资金流入2652.43万港元，流出3278.74万港元。君实生物股票所在的生物技术行业中，整体跌幅为4.74%。其相关个股中，中生北控生物科技、嘉和生物、帝王国际投资涨幅较大，振幅较大的相关个股有瑞博生物-B、中慧生物-B、百奥赛图-B，振幅分别为15.41%、13.59%、12.17%。药品批发,药品委托生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202145801a6c91efb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202145801a6c91efb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1515","BK1161"],"gpt_icon":0},{"id":"2608896737","title":"荣昌生物、科兴制药、君实生物等多家创新药企2025业绩战况如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2608896737","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608896737?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:25","pubTimestamp":1769999139,"startTime":"0","endTime":"0","summary":"1月30日，包括荣昌生物、科兴制药、君实生物、百利天恒、复旦张江等多家创新药企业发布2025年业绩预告，那么2025年这些药企战绩如何？而科兴制药更是预计，2025年归母净利润同比增长328.83%至455.89%，为1.35亿元至1.75亿元。科兴制药表示，创新药管线突破奠定业绩增长基础。与荣昌生物、科兴制药的强势增长不同，百利天恒、复旦张江等则面临不同程度的业绩压力，但各有应对与布局。各家创新药企业的业绩表现，背后是2025年国产创新药行业的结构性改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202104016a6c84b5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202104016a6c84b5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06978","01877","09995","BK1515","BK1191","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1583","01349"],"gpt_icon":0},{"id":"2608778300","title":"每周股票复盘：君实生物（688180）预计2025年亏损收窄至8.73亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608778300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608778300?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:16","pubTimestamp":1769883373,"startTime":"0","endTime":"0","summary":"业绩披露要点君实生物发布业绩预告，预计2025年全年归属净利润亏损约8.73亿元，亏损同比减少31.85%。公司公告汇总上海君实生物医药科技股份有限公司2026年度第一期科技创新债券已成功发行，募集资金于2026年1月26日到账。本期债券名称为上海君实生物医药科技股份有限公司2026年度第一期科技创新债券，简称26君实生物MTN001(科创债)，代码102680280，期限3+2年，起息日为2026年1月26日，兑付日为2031年1月26日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1583","688180","BK0239","BK1515","01877"],"gpt_icon":0},{"id":"2607801466","title":"君实生物(01877)发盈警 预期2025年归母净亏损为8.73亿左右 同比亏损减少 31.85%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2607801466","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607801466?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:08","pubTimestamp":1769771285,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物 公布，预计 2025 年年度实现营业收入25亿元左右，同比增长 28.32%左右。预计 2025 年年度实现归属于母公司所有者的净亏损为8.73亿左右，同比亏损减少 31.85%左右。报告期内，公司营业收入增长，主要系商业化药品的销售收入与上年同期相比有所增长。其中，JS207 目前已处于 II 期临床研究阶段，正在多个瘤种中开展与化疗、单抗、ADC 等不同药物的联合探索，JS207 与 JS212 联合用药的 II 期临床试验正在进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1515","BK1583","688180","BK1161","01877"],"gpt_icon":0},{"id":"2607702637","title":"君实生物跌6.02% 连亏9年3季2020年上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2607702637","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607702637?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:03","pubTimestamp":1769677399,"startTime":"0","endTime":"0","summary":"中国经济网北京1月29日讯 君实生物 今日收报36.82元，跌幅6.02%。该股目前处于破发状态。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票募的发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260129/31983200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK1515","01877","BK1583","688180","BK1161"],"gpt_icon":0},{"id":"2606791714","title":"每日卖空追踪 | 君实生物 01月28日卖空量成交27.32万股，卖空比例为3.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606791714","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606791714?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:30","pubTimestamp":1769589025,"startTime":"0","endTime":"0","summary":"君实生物北京时间01月28日，跌5.07%，卖空量成交27.32万股，较上一交易日减少90.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128164714a45f8aff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128164714a45f8aff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01877","BK1515"],"gpt_icon":0},{"id":"2606209791","title":"君实生物01月28日主力净流出1566.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209791","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606209791?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:15","pubTimestamp":1769588150,"startTime":"0","endTime":"0","summary":"01月28日, 君实生物股价跌5.07%，报收22.86元，成交金额2.1亿元，换手率3.40%，振幅6.64%，量比1.32。君实生物今日主力资金净流出1566.1万元，上一交易日主力净流入302.1万元。该股近5个交易日下跌1.72%，主力资金累计净流出159.0万元；近20日主力资金累计净流入343.1万元，其中净流入天数为8日。该股主力净额占比0.26%，港股市场排名2685/2707。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162253a45f7488&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162253a45f7488&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","BK1161","01877"],"gpt_icon":0},{"id":"2606917947","title":"武汉病毒研究所，有新发现","url":"https://stock-news.laohu8.com/highlight/detail?id=2606917947","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606917947?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:08","pubTimestamp":1769515722,"startTime":"0","endTime":"0","summary":"图源/央视新闻不过，中国科学院武汉病毒研究所官微披露，肖庚富/张磊砢研究员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限公司胡天文博士在国际期刊Emerging Microbes & Infections上发表了题为“The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection”的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗病毒活性，为这一高致死性新发传染病的防治带来新希望。尼帕病毒疫情持续发酵，带动市场对高致病性病毒检测领域的关注，IVD板块情绪升温。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127201438a6b30c9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127201438a6b30c9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02630","01877","BK1191","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2606201471","title":"1月27日君实生物涨7.96%，中信建投医改混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201471?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502907,"startTime":"0","endTime":"0","summary":"证券之星消息，1月27日君实生物涨7.96%创60日新高，收盘报40.98元，换手率6.7%，成交量51.32万手，成交额20.23亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共22家，其中持有数量最多的公募基金为中信建投基金的中信建投医改混合A。中信建投医改混合A目前规模为4.75亿元，最新净值1.8143，较上一交易日下跌1.14%，近一年上涨24.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700026997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1161","BK1583","BK1515","01877","601066","BK0276","BK0239"],"gpt_icon":0},{"id":"2606014782","title":"君实生物涨7.96%，太平洋二个月前给出“买入”评级，目标价51.16元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606014782","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606014782?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:34","pubTimestamp":1769502893,"startTime":"0","endTime":"0","summary":"今日君实生物涨7.96%，收盘报40.98元。2025年10月30日，太平洋研究员周豫,戎晓婕发布了对君实生物的研报《拓益收入同比增长40%，持续关注PD-1/VEGF数据读出》，该研报对君实生物给出“买入”评级，认为其目标价为51.16元，现价距离目标价尚有24.84%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为71.63%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的韩世通。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700026990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877","601099"],"gpt_icon":0},{"id":"2606188209","title":"智通AH统计|1月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2606188209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606188209?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:15","pubTimestamp":1769501707,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月27日收盘，东北电气、浙江世宝、京城机电股份分列AH溢价率前三位，溢价率分别为800.00%、351.95%、269.91%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-12.95%、-3.26%、-2.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HPAD.SI","01880","02338","03143","00300","00638","02359","00553","00187","06031","002594","BYDDY","PAImain","02691","02628","82318","01057","01877","01108","LU0348816934.USD","02218","00358","02318","03750","03968","02009","159982","03145","03678","00317","06185","01033","399300","01528","00042","01398","81211","PNGAY","01349","HYDD.SI","01618","601318","01276","01812"],"gpt_icon":1},{"id":"2606271217","title":"港股君实生物一度涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606271217","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606271217?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:40","pubTimestamp":1769485202,"startTime":"0","endTime":"0","summary":"每经AI快讯，君实生物(01877.HK)一度涨超5%，截至发稿涨4.55%，报24.84港元，成交额1.79亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631958757.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631958757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","688180","BK0239","BK1515","01877"],"gpt_icon":0},{"id":"2606210482","title":"智通港股解盘 | 霍尔木兹海峡引发市场忧虑 资产类持续受到追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2606210482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606210482?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:36","pubTimestamp":1769431016,"startTime":"0","endTime":"0","summary":"伊朗政权准备应对袭击，据报道，伊朗最高领袖哈梅内伊已进入德黑兰一处加固地堡。多地SKP门店数据显示，高端黄金消费热度延续并进一步升温。报道指出，1月24日开业当日7点，排队人数达到数百人。铀价有望持续走强。对此，长和发公告指，未有就现有电讯或零售资产及业务交易，包括独立上市作出决定。不过预计进入2027财年关店幅度有望收窄，以及海外市场拓展带来增量贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00883","01088","00081","01686","BK1528","HTCD.SI","01164","LU0683595622.HKD","LU0738912210.USD","03896","01258","01877","80016","LU0048388663.USD","01138","00014","LU0314109678.HKD","06181","80883","00460","02883","SUHJY","01898","02013","01929","02099","02579","02259","03145","00857","LU0828238088.HKD","LU1328615791.USD","LU0254981946.USD","00016","00817","03121","06185","01171","LU1282649141.HKD","LU0543330483.HKD","LU1023057109.AUD","SG9999017495.SGD","AI","00001","01277","LU1044876610.USD"],"gpt_icon":1},{"id":"2606599210","title":"君实生物(01877)完成发行10亿元科技创新债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2606599210","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606599210?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:33","pubTimestamp":1769430808,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，近日，公司已完成发行2026年度第一期科技创新债券，募集资金已于2026年1月26日到账。2026年度第一期科技创新债券发行总金额为人民币10亿元，期限为3+2年，于2031年1月26日到期，发行利率为2.70%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK0239","BK1583","BK1515","BK1161","BK4581","688180","BK4585","BK4588"],"gpt_icon":0},{"id":"2606296482","title":"港股异动 | 部分医药股午后拉升 康希诺生物(06185)超10% 君实生物(01877)涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606296482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606296482?lang=zh_cn&edition=full","pubTime":"2026-01-26 13:44","pubTimestamp":1769406244,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，部分医药股午后拉升。截至发稿，康希诺生物涨10.13%，报40.86港元；君实生物涨5.19%，报23.92港元；复旦张江涨4.11%，报3.29港元。消息面上，1月26日，印度出现尼帕病毒疫情相关话题冲上热搜，引发关注。公开资料显示，尼帕是人畜共患的RNA病毒，主要由果蝠和猪携带，死亡率在40%至75%之间，潜伏期一般为4天至14天。目前尚无专门的疫苗和有效疗法，治疗侧重于控制症状和提供支持性护理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1515","09939","BK1161","BK1191","06185","688180","BK1583","01877","BK0239","01349"],"gpt_icon":0},{"id":"2606326296","title":"【券商聚焦】招银国际：创新药出海趋势长期将延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2606326296","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606326296?lang=zh_cn&edition=full","pubTime":"2026-01-26 13:17","pubTimestamp":1769404672,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2026年初至今累计上涨9.2%，跑赢MSCI中国指数5.6%。展望2026年，创新药出海趋势长期将延续，该机构将重点关注已出海管线的临床进展与数据兑现的核心催化。年初多个创新药BD交易落地，中国创新药出海的趋势向好。该机构认为，中国企业对于临床前分子的转让或将谨慎，未来中国出海分子将大多在具备中国早期临床试验数据的基础上达成，以获得更高的交易价值。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973928","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","02269","02616","LU0456827905.SGD","06185","LU1807302812.USD","BK1588","LU0359201612.USD","LU1880383366.USD","SG9999002463.SGD","01177","LU2399975544.HKD","06978","01877","LU0043850808.USD","LU0417516902.SGD","LU1242518931.SGD","09688","SG9999002562.SGD","LU0979878070.USD","01801","LU0315179316.USD","LU0588546209.SGD","LU0516422440.USD","BK1576","LU0516423091.SGD","LU0348825331.USD","02142","LU0708995583.HKD","IE00B5MMRT66.SGD","01093","LU0516422952.EUR","LU1226287875.USD","06160","LU0348784397.USD","LU1303224171.USD","09926","IE00B031HY20.USD","BK1500","LU1969619763.USD","09995","LU1794554557.SGD","LU1960683339.HKD","LU3063872942.SGD","LU2242644610.SGD","LU1226287529.USD","IE00BZ08YT58.USD","LU0051755006.USD","IE00BZ08YS42.EUR","LU0348767384.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.1387},{"period":"1month","weight":-0.0691},{"period":"3month","weight":-0.1961},{"period":"6month","weight":-0.2397},{"period":"1year","weight":0.9566},{"period":"ytd","weight":-0.0281}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.064045},{"month":3,"riseRate":0.714286,"avgChangeRate":0.049127},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}